Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a global biotechnology company with an innovative peptide drug discovery platform, including a late stage candidate approaching commercialization. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market already. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand has established strategic partnership with Boehringer Ingelheim, Beta Bionics and Alexion Pharmaceuticals.
Zealand is based in Copenhagen (Glostrup), Denmark and Boston and New York City, USA. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.